期刊文献+

Experimental research of pulmonary injury on irradiation combined with pemetrexed

培美曲塞联合放疗对肺损伤的实验研究(英文)
下载PDF
导出
摘要 Objective: The aim of our study was to examine whether irradiation combined with pemetrexed can exacerbate pulmonary injury. Methods: Two groups of male Wister Rats were subjected to bilateral apex of lungs irradiation(a single dose of 12 Gy), with or without pemetrexed(20 mg/kg) by intraperitoneal injection at the same time; a third group of weightand age- matched animals were treated with pemetrexed alone, as the same dose scheme, time and root of injection. The fourth group served as control. The whole lung mounts were dissected to histological evaluation, while serum cytokine transforming growth factor-β1(TGF-β1) analysis were compared at 1, 7, 21, 35, 49 days post-irradiation after irradiation. Results: Histological examination showed a thickening of alveolar septal, accumulation of inflammatory cells. The irradiation treatment group and the radiation-chemo treatment group showed a statistically significant higher level of TGF-β1(P < 0.05) than other two groups, but there were no differences between these two irradiation groups. Conclusion: These results demonstrated that pemetrexed can not aggravate pulmonary injury and it could be safely used in concurrent or sequential radio-chemotherapy in lung adenocarcinoma.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第4期153-156,共4页 中德临床肿瘤学杂志(英文版)
关键词 radiation-induced pulmonary injury transforming growth factor-β1 (TGF-β1) PEMETREXED 照射治疗 肺损伤 组织学检查 实验 合并 腹腔注射 TGF-β 生长因子
  • 相关文献

参考文献1

二级参考文献16

  • 1Demarinis F,Paul S,Hanna N,et al.Survival update for the phase III study of pemetrexed vs.docetaxel in non-small cell lung cancer (NSCLC).J Clin Oncol,2006,24:397–397.
  • 2Hanan N,Shepherd FA,Fossella FV,et al.Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previous treated with chemotherapy.J Clin Oncol,2004,22:1589–1597.
  • 3Scagliotti GV,Parikh P,Von PJ,et al.Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo-therapy-naive patients with advanced-stage non-small-cell lung can-cer.J Clin Oncol,2008,26:3543–3551.
  • 4Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors.J Natl Cancer Inst,2000,92:205–216.
  • 5Sun Y.Medical oncology.Beijing:People Health Press,2001.324– 340.
  • 6Schiller JH,Harrington D,Belani CP,et al.Comparison of four che-motherapy regimens for advanced non-small-cell lung cancer.N Engl J Med,2002,346:92–98.
  • 7Shih C,Chen VJ,Gossett LS,et al.LY231514,a pyrrolo[2,3-d] pyrim-idine-based antifolate that inhibits multiple folate-requiring enzymes.Cancer Res,1997,57:1116–1123.
  • 8Giorgio S,Nasser H,Frank F,et al.The differential efficacy of pemetrexed according to NSCLC histology:a review of two phase III studies.Oncologist,2009,14:253–263.
  • 9Syrigos KN,Vansteenkiste J,Parikh P,et al.Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.Ann Oncol,2010,21:556–561.
  • 10Ciuleanu TE,Brodowicz C,Belani CP,et al.Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC:A phase III study.J Clin Oncol,2008,26:8011.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部